Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

pathogen-specific CTLs

Preclinical

SShenzhen Geno-Immune Medical Institute

1

Indications

1

Total Trials

1

Active Trials

0

Competitors

Timeline

Expected Milestones

Q4 2030

PreclinicalRecruiting

Infection

NCT03159364

Clinical

Trials by Indication[1]

Infection1 trial

Phase I/II Multicenter Trial of Antigen-specific Cytotoxic T Cells in the Treatment of Opportunistic Infections

Recruiting·SShenzhen Geno-Immune Medical Institute·Preclinical·NCT03159364·100 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for pathogen-specific CTLs. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for pathogen-specific CTLs. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Shenzhen Geno-Immune Medical Institute company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Preclinical[1]
Company: SShenzhen Geno-Immune Medical Institute

Related News